Transcatheter arterial chemoembolization

Transcatheter Arterial Chemoembolization (TACE) is a minimally invasive procedure used in the treatment of certain types of cancer, most notably hepatocellular carcinoma (HCC), which is a primary liver cancer. This procedure combines two therapeutic approaches: targeted chemotherapy and embolization. TACE is designed to deliver high doses of chemotherapy directly to the tumor while restricting the tumor's blood supply by embolizing, or blocking, the arteries feeding the tumor.

Procedure

The TACE procedure involves the insertion of a catheter through the femoral artery in the groin or the radial artery in the wrist. Using fluoroscopy (live X-ray) for guidance, the catheter is navigated into the arteries supplying the tumor within the liver. A chemotherapy drug, often combined with a substance that embolizes the artery, is then injected directly into the blood vessels feeding the tumor. The embolizing agent ensures that the chemotherapy is concentrated in the tumor area by blocking the blood flow, which helps to starve the tumor of nutrients and oxygen while also minimizing systemic exposure to the chemotherapy drugs.

Indications

TACE is primarily indicated for patients with intermediate-stage HCC who are not candidates for curative treatments such as surgery or liver transplantation. It may also be used in certain cases of metastatic liver cancer, where the cancer has spread to the liver from another part of the body.

Benefits and Risks

The main benefit of TACE is its ability to directly target the tumor with high doses of chemotherapy while sparing the rest of the liver and body from exposure. This can lead to a reduction in tumor size and a slowing of disease progression, potentially improving survival and quality of life for patients with liver cancer.

However, TACE is not without risks. Complications can include liver damage, infection, bleeding, and reactions to the chemotherapy drugs. The procedure is generally well-tolerated, but it is not suitable for all patients, particularly those with poor liver function or significant heart or kidney problems.

Outcomes

The outcomes of TACE vary depending on several factors, including the size and number of liver tumors, the patient's overall liver function, and the presence of any underlying liver diseases such as hepatitis or cirrhosis. While TACE can be effective in controlling tumor growth and prolonging survival, it is not considered a cure for liver cancer.

Recent Developments

Recent advancements in TACE include the use of drug-eluting beads (DEBs), which are microspheres that can be loaded with chemotherapy drugs and delivered to the tumor through the catheter. DEBs provide a more controlled release of the chemotherapy over time, potentially increasing the effectiveness of the treatment and reducing side effects.

Conclusion

TACE represents a critical option in the management of certain liver cancers, offering a balance between efficacy and tolerability for patients who are not candidates for more invasive treatments. Ongoing research and development in the field of interventional oncology continue to refine and expand the role of TACE in cancer care.

‎